← boardnext 2026-12
NVCT
Nuvectis Pharma, Inc.distress 3/10 · well-funded / low risk$19.86+3%today-30% from 52w high
Oncology 1
Lead: Advanced Solid Tumor
Revenue
pre-revenue
Liquidity
$25M
Runway
1.4 yrs
Shares 1y
+4%
Price & events
+126.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.0%
1D
+6.8%
1W
+13.2%
1M
+125.9%
3M
+131.2%
6M
+152.7%
1Y
+195.5%
2Y
—
5Y
+511.1%
All
Overview
- Market Cap
- $526.80M
- Volume
- 45.48K
- 52 Week Range
- $5.65 – $28.53
- Total Shares
- 26.53M
- Float Shares
- 16.98M
- Short %
- 11.56%
- % Held by Insiders
- 35.49%
- % Held by Institutions
- 14.43%
- RVOL
- 0.10x
- Beta
- -0.25
Pipeline stages · 2 programs
NXP900
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
NXP800
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2026-12-31 | Phase 1 | NXP900, Osimertinib | EGFR Mutation Positive Non-small Cell Lung Cancer, EGFR Mutated Non-small Cell Lung Cancer Patients | — | recruiting |
| 2027-03 Estimated 50% readout ~2027-03-31 | Phase 1 | NXP900 | Advanced Solid Tumor, NSCLC (Non-small Cell Lung Cancer), Renal Cancer, Mesothelioma, Non-Small Cell Squamous Lung Cancer, Non-small Cell Lung Adenocarcinoma | — | recruiting |
| 2025-12 | Phase 1 | NXP800orphan | Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation | 45 | active not recruiting |
Catalyst news & presentations · 3
- 2026-08-04Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-22partnershipExclusive license for NXP100 and NXP200 in ex-China territories from Haisco Pharmaceutical Group.SEC 8-K
- fall 2024readoutPhase 1NXP800 · Data update from Phase 1b clinical trialSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $32 (+60% upside) · 5 analysts
- 2026-07-06Roth CapitalBuy
- 2026-06-22HC Wainwright & Co.Buy
- 2026-06-12HC Wainwright & Co.Buy
- 2025-08-04HC Wainwright & Co.Buy
- 2025-04-30HC Wainwright & Co.Buy
- 2025-04-02Maxim GroupBuy
Competitors — Advanced Solid Tumor
- ABBVAbbVie Inc.$451.1B · D2
- NVSEFNOVARTIS AG$292.0B · D3
- RVMDRevolution Medicines, Inc.$40.3B · D1
- BEIGFBeOne Medicines Ltd.$31.7B · D1
- CELG-RIBRISTOL MYERS SQUIBB CO$241M · D2
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- BCYCBICYCLE THERAPEUTICS PLC$124M · D4
- XLOXilio Therapeutics, Inc.$50M · D1
- APREAprea Therapeutics, Inc.$8M · D6
Recent news
- 2026-07-23Correction: (Title Correction) Nuvectis Announces Marketing - GlobeNewswire
- 2026-07-23China approves Nuvectis’ ciprocopan for blood disorder PNH By Investing.com - Investing.com Australia
- 2026-07-23Ciprocopan (NXP100) Receives Marketing Approval in China - GlobeNewswire
- 2026-07-23Nuvectis Drug Reached 12 g/dL in 59.5% of PNH Patients - Stock Titan
- 2026-07-18+$602 Day Trading Live Recap - Scalped Stocks: $ISPO $NVCT $ANGH Strickland Vs Khamzat (onWDLRKuz9) - Mshale
- 2026-07-16NVCT Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor Sentiment - Profit Growth Outlook - dars.gov.et
- 2026-07-15+$602 Day Trading Live Recap - Scalped Stocks: $ISPO $NVCT $ANGH Strickland Vs Khamzat (onWDLRKuz9) - Mshale
- 2026-07-15Wall Street analysts see a 61.46% upside in Nuvectis Pharma (NVCT): Can the stock really move this high? - MSN
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.